Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys
- PMID: 8955203
Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys
Abstract
Variants of SIV containing a deletion in the nef gene are attenuated in adult macaques, where they provide protection from challenge with pathogenic SIV, but the mechanism of protection remains unknown. One of these attenuated variants carrying deletions in nef, vpr, and NRE (SIVmac239delta3) was recently found to be pathogenic in infant macaques exposed to the virus at birth. We investigated whether inadequate or inappropriate antiviral humoral immune responses could explain why this virus causes disease in infant macaques. Plasma samples from four infants infected with SIVmac251 and five infants and two adults infected with SIVmac239delta3 were evaluated for neutralizing Abs to a laboratory-passaged stock of SIVmac251, an animal challenge stock of SIVmac239/nef-open, and a stock of SIVmac239delta3 to which animals were exposed. Plasma samples were evaluated further for complement-mediated Ab-dependent enhancement (C'-ADE) of SIVmac239/nef-open in vitro. High-titer neutralizing Abs to SIVmac251 were detected in plasma samples from adults and most infants within 3 to 5 wk of infection with either virus. Neutralizing Abs to SIVmac239/nef-open and SIVmac239delta3 developed more slowly, being undetectable before 23 to 63 wk of infection. Timing, magnitude, and breadth of neutralizing Ab responses did not correlate with progression to disease or lack thereof and gave no indication of an impaired humoral immune response in infants. Furthermore, C'-ADE was detected equally in plasma samples from adults and infants. The results indicate that infection with SIVmac239delta3 causes disease in infant macaques despite their mounting of antiviral humoral immune responses comparable to those of adults.
Similar articles
-
Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus.J Virol. 1998 Aug;72(8):6950-5. doi: 10.1128/JVI.72.8.6950-6955.1998. J Virol. 1998. PMID: 9658152 Free PMC article.
-
Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa.Virology. 1997 Mar 3;229(1):143-54. doi: 10.1006/viro.1996.8419. Virology. 1997. PMID: 9123856
-
Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection.AIDS Res Hum Retroviruses. 1995 Aug;11(8):963-70. doi: 10.1089/aid.1995.11.963. AIDS Res Hum Retroviruses. 1995. PMID: 7492443
-
Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.Vaccine. 2006 Mar 10;24(11):1811-20. doi: 10.1016/j.vaccine.2005.10.026. Epub 2005 Oct 25. Vaccine. 2006. PMID: 16274888
-
"Attenuated" simian immunodeficiency virus in macaque neonates.AIDS Res Hum Retroviruses. 1996 Mar 20;12(5):459-60. doi: 10.1089/aid.1996.12.459. AIDS Res Hum Retroviruses. 1996. PMID: 8882333 Review. No abstract available.
Cited by
-
Efficacy of AIDS vaccine strategies in nonhuman primates.Med Microbiol Immunol. 2005 Aug;194(4):201-6. doi: 10.1007/s00430-005-0238-5. Epub 2005 Apr 21. Med Microbiol Immunol. 2005. PMID: 15843997 Review.
-
Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals.Virol J. 2005 Feb 14;2:11. doi: 10.1186/1743-422X-2-11. Virol J. 2005. PMID: 15710048 Free PMC article.
-
Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus.J Virol. 1998 Aug;72(8):6950-5. doi: 10.1128/JVI.72.8.6950-6955.1998. J Virol. 1998. PMID: 9658152 Free PMC article.
-
Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections.J Virol. 1998 Oct;72(10):7852-9. doi: 10.1128/JVI.72.10.7852-7859.1998. J Virol. 1998. PMID: 9733822 Free PMC article.
-
A vaccine for HIV type 1: the antibody perspective.Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10018-23. doi: 10.1073/pnas.94.19.10018. Proc Natl Acad Sci U S A. 1997. PMID: 9294155 Free PMC article. Review.